MK-0752
- Generic Name
- MK-0752
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21ClF2O4S
- CAS Number
- 471905-41-6
- Unique Ingredient Identifier
- 9JD9B4S53T
- Background
Mk 0752 is under investigation in clinical trial NCT00572182 (MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 65
- Registration Number
- NCT01295632
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 47
- Registration Number
- NCT01243762
Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Loyola University
- Target Recruit Count
- 22
- Registration Number
- NCT00756717
- Locations
- 🇺🇸
Loyola Univeristy Medical Center, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States
MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer
Phase 1
Terminated
- Conditions
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2012-03-06
- Lead Sponsor
- Pediatric Brain Tumor Consortium
- Target Recruit Count
- 33
- Registration Number
- NCT00572182
- Locations
- 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath